Concurrent Retinoblastoma 1 ( RB1 ) and IKZF1 Deletions Have Adverse Outcome in Childhood B‐Cell Acute Lymphoblastic Leukemia (B‐ALL)
International Journal of Laboratory Hematology · 2026
DOI: 10.1111/ijlh.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Gadha Krishna Leons und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India. Hauptthemen laut MEDLINE: Ikaros Transcription Factor, Ubiquitin-Protein Ligases, Gene Deletion, Retinoblastoma Binding Proteins. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Indian Council of Medical Research, All-India Institute of Medical Sciences.
Abstract (Originalsprache)
Introduction
The B‐ALL risk‐stratification needs improvement. The prevalence and impact of Retinoblastoma 1, that is, RB transcriptional corepressor 1 ( RB1 ) deletion in pediatric B‐ALL, alone and in concurrence with IKAROS family zinc finger 1 ( IKZF1 ) deletion was estimated.
Methods
Multiplex ligation‐dependent probe amplification (MLPA) was used to analyze the pediatric B‐ALL cases for gene deletions. The cases were divided into subgroups based on RB1 deletions and IKZF1 deletions. IKZF1plus profile ( IKZF1 and additional CDKN2A/B , PAX5 , pseudoautosomal region deletion in absence of ERG deletion) was also noted.
Results
In 517 patients with median age 7 years (1–18), 41 (7.9%) had RB1 deletion and 99 (19.1%) IKZF1 deletion. Concurrent RB1 and IKZF1 deletions were 14 (2.7%), RB1 deletion without IKZF1 deletion 27 (5.2%), IKZF1 deletion without RB1 deletion 85 (16.4%), and none of RB1 or IKZF1 deletion 391 (75.6%). Of the treated patients ( n = 465), cases with concurrent RB1 and IKZF1 deletions had the worst post‐induction remission rate (54.6%; p = 0.019) compared to cases lacking RB1 or IKZF1 deletions (86%). The median event‐free and overall survival were poor in cases with concurrent RB1 and IKZF1 deletions (8.9 months; p = 0.0002 and 11.5 months; p = 0.007 respectively) compared to cases lacking RB1 or IKZF1 deletions (41.4 months, and not reached respectively). The cases with RB1 deletion along with IKZF1plus profile had a trend of early deaths and relapses compared to IKZF1plus alone.
Conclusions
The B‐ALL patients with concurrent RB1 and IKZF1 deletions had worse outcomes compared to cases without any of these deletions. The RB1 deletion increased the risk of early events in patients with the IKZF1plus profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Department of Medical Oncology, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
ORCID-Profile: Gadha Krishna Leons, Sanjeev Kumar Gupta, Smeeta Gajendra
Förderung
- Indian Council of Medical Research
- All-India Institute of Medical Sciences
Zitieren
APA
Krishna Leons, G., Sharma, P., Gupta, S. K., Bakhshi, S., Gupta, R., Gajendra, S., & Pushpam, D. (2026). Concurrent Retinoblastoma 1 ( RB1 ) and IKZF1 Deletions Have Adverse Outcome in Childhood B‐Cell Acute Lymphoblastic Leukemia (B‐ALL). International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70069
Vancouver
Krishna Leons G, Sharma P, Gupta SK, Bakhshi S, Gupta R, Gajendra S, et al. Concurrent Retinoblastoma 1 ( RB1 ) and IKZF1 Deletions Have Adverse Outcome in Childhood B‐Cell Acute Lymphoblastic Leukemia (B‐ALL). International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70069
BibTeX
@article{KrishnaLeons2026,
author = {Krishna Leons, Gadha and Sharma, Preity and Gupta, Sanjeev Kumar and Bakhshi, Sameer and Gupta, Ritu and Gajendra, Smeeta and Pushpam, Deepam},
title = {Concurrent Retinoblastoma 1 ( RB1 ) and IKZF1 Deletions Have Adverse Outcome in Childhood B‐Cell Acute Lymphoblastic Leukemia (B‐ALL)},
journal = {International Journal of Laboratory Hematology},
year = {2026},
doi = {10.1111/ijlh.70069}
}
EUVIMED